Name:
Bempedoic Acid and Diabetes
Description:
Bempedoic Acid and Diabetes
Thumbnail URL:
https://cadmoremediastorage.blob.core.windows.net/64dbd0c1-46ec-4b04-94c1-40c36cd48406/thumbnails/64dbd0c1-46ec-4b04-94c1-40c36cd48406.jpeg?sv=2019-02-02&sr=c&sig=byO%2BUMsyJyjpz7%2FcgJbwIYmfhw%2FCY5P8p5CbcsNZZDc%3D&st=2024-12-21T15%3A57%3A12Z&se=2024-12-21T20%3A02%3A12Z&sp=r
Duration:
T00H03M33S
Embed URL:
https://stream.cadmore.media/player/64dbd0c1-46ec-4b04-94c1-40c36cd48406
Content URL:
https://cadmoreoriginalmedia.blob.core.windows.net/64dbd0c1-46ec-4b04-94c1-40c36cd48406/18777611.mp3?sv=2019-02-02&sr=c&sig=AWp6FNY1KUYuOq%2B%2Bkmxy6C9rNfye9EeoAs051WWVuos%3D&st=2024-12-21T15%3A57%3A12Z&se=2024-12-21T18%3A02%3A12Z&sp=r
Upload Date:
2022-02-28T00:00:00.0000000
Transcript:
Language: EN.
Segment:0 .
>> Practice Impact Extra podcasts are derived from Hurst's, The Heart Board Review, and other online resources available only through accesscardiology.com. >> Previously, increased diabetic risk development has been seen with some of the newer lipid-lowering agents. So what's new with bempedoic acid? [ Music ] >> Hi, Dr. Bernie here, and welcome again to Practice Impact Extra. Bempedoic acid is a new FDA approved lipid-lowering agent reporting overall efficacy in lowering of LDL.
As a new lipid-lowering medication, it creates interest in how it may affect glycemia. PrimeMed analysis showed about 10% increase in the new onset of diabetes in statin users. Present findings that were presented at the ADA scientific session in June 2020 provided an analysis of bempedoic acid efficacy and safety in patients with diabetes, prediabetes, or normoglycemia.
Four Phase III trials were pooled, including 3,623 patients. The majority, 75% to 84%, had atherosclerotic cardiovascular disease. Patients were randomized to bempedoic acid, 180 milligrams a day, or placebo. The primary outcome was measured and reported at 12 weeks. LDL cholesterol at 12 weeks was significantly lower in those patients who received bempedoic acid compared to placebo, regardless of whether the person and patient had diabetes, prediabetes, or no diabetes.
Also noted that there was a significant decrease in C-reactive protein, ApoB, and total cholesterol. But it's very important to note that the hemoglobin A1C did not increase and was actually significantly lower in patients with prediabetes and diabetes on bempedoic acid versus placebo. The safety profile also was similar to placebo and did not vary by the glycemic status.
So what's the take home message? These results demonstrating modest LDL-lowering effect and overall safety in bempedoic acid, regardless of the glycemic status, and did that lead to an increase in new onset diabetes. This trial analysis was not designed as a cardiovascular outcome trial. The randomized clear cardiovascular outcome trial is now in Phase III and has already enrolled 14,000 patients.
We anxiously will await the results of this outcome trial. Till then, I believe the discussion with the patient is necessary regarding the known efficacy, safety, and pending cardiovascular outcomes when prescribing bempedoic acid. Thank you for joining me. And see you next time on Practice Impact Extra. >> We hope you enjoyed this podcast from McGraw-Hill. Subscribers to AccessCardiology have instant access to over 25,000 pages of rich medical content, receive medical updates from trusted experts, and have access to other special features.
To subscribe or learn more, please visit accesscardiology.com.
